Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 283-144-9 | CAS number: 84540-50-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24.06. - 21.10.2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2005
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- see field "Any information on materials and methods"
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.26 (Sub-Chronic Oral Toxicity Test: Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- other: EPA 712-C-98-199, 90-Day Oral Taxicity in Rodents, 1998
- GLP compliance:
- yes
Test material
- Reference substance name:
- 3-amino-2-chlor-6-methylphenol
- EC Number:
- 283-144-9
- EC Name:
- 3-amino-2-chlor-6-methylphenol
- Cas Number:
- 84540-50-1
- Molecular formula:
- C7H8ClNO
- IUPAC Name:
- 3-amino-2-chloro-6-methylphenol
- Test material form:
- other: beige powder
- Details on test material:
- molecular weight: 157.5
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Recognised by international guidelines as the recommended test system.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age: Approx. 6 weeks
Females were nulliparous and non-pregnant.
Conditions:
Animals were housed in a controlled environment, in which optimal conditions were considered to be approximately 15 air changes per hour, a temperature of 21.0 ± 3.0°C (actual range: 17.3 - 24.9°C), a relative humidity of 30-70% (actual range: 30 - 100%) and 12 hours artificial fluorescent light and 12 hours darkness per day. Temporary fluctuations from the light/dark cycle (with a maximum of 1 hour) occurred due to performance of functional observations in the room. Based on laboratory historical data, these fluctuations were considered not to have affected the study integrity.
Accommodation:
Group housing of 5 animals (recovery group allocation) or 4 animals (main group allocation) per sex per cage in stainless steel suspended cages with wire mesh floors (55 x 34 x 21.5 cm height). Acclimatisation period was at least 5 days before start of treatment under laboratory conditions. During activity monitoring, animals were individually housed overnight in Macrolon plastic cages (type 111, height 15 cm.) with sterilised sawdust (Woody-Clean type 3/4, TecnilabBMI BV, Someren, The Netherlands) provided as bedding. Results of bedding analyses for contaminants are examined and archived.
Diet:
Free access to standard pelleted laboratory animal diet (from Altrom in code VRF-1, Lage, Germany).
Animals were dosed up to the day prior to necropsy.
Water:
Free access to tap water.
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- Dose volume: 10 ml/kg body weight. Actual dose volumes were calculated weekly according to the latest body weight.
- Vehicle:
- propylene glycol
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Once daily for at least 90 days, 7 days per week, approximately the same time each day with a maximum of 6 hours difference between the earliest and latest dose.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- group 1 (vehicle control)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- group 2
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Remarks:
- group 3
- Dose / conc.:
- 600 mg/kg bw/day (nominal)
- Remarks:
- group 4
- No. of animals per sex per dose:
- 12
- Control animals:
- yes
- Details on study design:
- Repeated dose 90-Day oral toxicity study with A 094 by daily gavage in the rat, followed by a 28-day recovery period.
Based on a 28-day range finding study, the dose levels for this 90-day oral gavage study were selected to be 0, 100, 300 and 600 mg/kg/day.
The test substance was administered daily for at least 90 days by oral gavage to SPF-bred Wistar rats. One control group and three treated groups were tested,each consisting of 12 males and 12 females. An additional 5 animals per sex in the control and high dose group were allowed 28 days of recovery. The following parameters were evaluated: clinical signs daily; functional observation tests; body weight and food consumption weekly; ophthalmoscopy at pretest and in
week 13; clinical pathology and macroscopy at termination; organ weights and histopathology on a selection of tissues.
Examinations
- Observations and examinations performed and frequency:
- Mortality/Viability:
At least twice daily. The time of death was recorded as precisely as possible.
Clinical signs:
At least once daily, detailed clinical observations were made in all animals. Once prior to start of treatment and at weekly intervals, this was also performed outside the home cage in a standard arena. The time of onset, degree and duration were recorded.
All symptoms were recorded and graded according to fixed scales: Maximum grade 1: grade O = absent, grade 1 = present
Maximum grade 3 or 4: grade 1 = slight, grade 2 = moderate, grade 3 = severe, grade 4 = very severe
Functional Observations:
During week 12-13 of treatment, the following tests were performed on all animals of the recovery groups and on all animals of the first cage of each main
group allocation (animal 26 replaced the decedent animal no. 22):
- hearing ability (HEARING), pupillary reflex (PUPIL L/R), static righting reflex (STATIC R) and grip strength (GRIP) (Score O = normal/present, score 1 = abnormal/absent).
- motor activity test (recording period: 12 hours during overnight for individual animals, using a computerised monitoring system, Pearson Technical Services, Debenham, Stowmarket, England). Based on the initial motor activity results, an additional motor activity measurement was performed in week 13 for animal nos. 11-14, 61-64, 81-84 and 131-134.
Ophthalmoscopic Examination ( direct):
Following instillation of tropicamide solution (5 mg/ml), both eyes were examined by means of an ophthalmoscope (Heine Beta 200): at pretest : All animals
at week 13 : Groups 1 and 4.
Body weights: Weekly.
Food consumption: Weekly
Water consumtion: Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected.
Results and discussion
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- clinical signs
- haematology
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 300 mg/kg bw/day (nominal)
- System:
- hepatobiliary
- Organ:
- kidney
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Wistar rats were treated with A 094 for 90 consecutive days by oral gavage, followed by a 28-day treatment-free recovery period.
One male at 100 mg/kg/day and one female at 600 mg/kg/day were found dead in week 7/8 of treatment. A cause of death could not be established microscopically. Since there were no apparent signs of toxicity during treatment and the mortality incidence was unrelated to the dose, these deaths were not regarded to be related to treatment.
Histopathological examination of the liver revealed centrilobular hypertrophy at 300 and 600 mg/kg/day, the effect being more marked in males than in females. At 600 mg/kg/day, these changes correlated with increased absolute and relative liver weights and significant deviations in clinical biochemistry parameters (increased cholesterol levels in males and females, reduced urea level in males, and increased alanine aminotransferase activity in females), and are suggestive of perturbations in liver function. Although there was no clear morphological evidence of hepatocellular necrosis, the increased ALAT levels do suggest that hepatocellular damage may have occurred at 600 mg/kg/day. At the end of the recovery period, centrilobular hepatocytic hypertrophy remained in evidence in all high dose males at slight severity. Hepatocytic hypertrophy was also noted at a minimal degree in one male only at 100 mg/kg/day, and occurred in the absence of any other supportive functional or morphological changes. Centrilobular hypertrophy of hepatocytes is frequently an adaptive change in response to treatment with xenobiotics and at low incidence and severity considered not to be adverse.
lncidental histologic alterations in males consisted of hepatocellular necrosis (ranging from focal to organising nature) and chronic inflammation. The incidence of these observations did not show a relation to the dose. In addition, various animals (primarily males) distributed among the dose groups displayed increased plasma alanine and/or aspartate aminotransferase activity levels at the end of treatment or recovery phase. There was no clear dose-related incidence and there was no clear relation to the necrotic lesions seen in the liver. Therefore, these changes were considered to be of no toxicological relevance.
An increased incidence of cortical tubular basophilia was observed in the kidneys of most high dose males. Furthermore, forestomach limiting ridge hyperplasia (with two cases of squamous hyperplasia of the forestomach) was noted in all high dose males at the end of treatment. These histological lesions were not apparent in females and had resolved at the end of the recovery phase. The limiting ridge hyperplasia probably represented a response to local irritation to test material residing in the forestomach, and is a commonly observed typical adaptive phenomenon in rodent studies. This finding is regarded to be of no relevance to man.
The brown discolouration of the urine observed among all groups of treated animals during treatment was probably caused by the test substance and/or a test substance metabolite and was not regarded as adverse.
The increased mean corpuscular volume values noted in males and females at 100 and 600 mg/kg/day and the decreased mean corpuscular haemoglobin concentration values noted in males at 100 and 600 mg/kg/day and in all groups of treated females are suggestive of macrocytic hypochromic erythrocytes in treated animals. However, there was little evidence for an anaemic response; only males at 600 mg/kg/day showed marginally reduced erythrocyte counts, while haemoglobin levels and red cell distribution width were essentially similar in all groups. These deviations were therefore regarded not indicative of an adverse effect on red blood cells.
The increased bilirubin and plasma potassium levels in high dose males may relate to the changes seen in red blood cell parameters, but may also relate to the effects noted in the liver and kidneys, respectively.
There were no effects on body weight gain, food intake, ophthalmoscopy and macroscopy findings.
From the results presented in this report a No Observed Adverse Effect Level (NOAEL) for A 094 was established at 100 mg/kg/day. - Executive summary:
Repeated dose 90·-Day oral toxicity study with A 094 by daily gavage in the rat, followed by a 28-day recovery period.
Based on a 28-day range finding study, the dose levels for this 90-day oral gavage study were selected to be 0, 100, 300 and 600 mg/kg/day.
The study was based on the following guidelines.
- EG Directive 67/548/EEC, B Repeated Dose (90 days) Toxicity (oral), 2001.
- OECD 408, Repeated Dose 90-day Oral Toxicity Study in Rodents, 1998.
- EPA 712-C-98-199, 90-Day Oral Toxicity in Rodents, 1998.
The test substance was administered daily for at least 90 days by oral gavage to SPF-bred Wistar rats. One control group and three treated groups were tested, each consisting of 12 males and 12 females. An additional 5 animals per sex in the control and high dose group were allowed 28 days of recovery.
The following parameters were evaluated: clinical signs daily; functional observation tests; body weight and food consumption weekly;
ophthalmoscopy at pretest and in week 13; clinical pathology and macroscopy at termination; organ weights and histopathology on a selection of tissues.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.